Oral Probiotic Bifidobacterium Longum Supplementation Improves Metabolic Parameters and Alters the Expression of the Renin-Angiotensin System in Obese Mice Liver
- 2020-07-23
- Biological Research For Nursing 23(1)
- A. S. Machado
- J. R. Oliveira
- D. F. Lelis
- A. D. de Paula
- A. Guimarães
- J. Andrade
- I. Brandi
- S. Santos
- PubMed: 32700545
- DOI: 10.1177/1099800420942942
Abstract
Background: Obesity and non-alcoholic fatty liver disease (NAFLD) have been increasing at an alarming rate worldwide. Bifidobacterium longum (BL), a common member of the human gut microbiota, has important health benefits through several mechanisms.
Objectives: We evaluated the BL supplementation effects on body metabolism and renin-angiotensin components hepatic expression in mice fed a high-fat diet.
Methods: Thirty-two male mice were divided into four groups: standard diet + placebo (ST), standard diet + Bifidobacterium longum (ST + BL), high-fat diet + placebo (HFD) and high-fat diet + Bifidobacterium longum (HFD + BL). Following the obesity induction period, the ST + BL and HFD + BL groups were supplemented with Bifidobacterium longum for 4 weeks. Then, body, biochemical, histological and molecular parameters were evaluated.
Results: HFD + BL mice had a significant decrease in adipose tissue mass and blood glucose levels, as well as a significant reduction in blood glucose during an intraperitoneal glucose tolerance test. The treatment also resulted in reduced levels of total cholesterol and hepatic fat accumulation. Moreover, we observed an increase in angiotensin converting enzyme 2 (ACE2) and Mas receptor (MASR) expression levels in BL-treated obese mice.
Conclusions: These data demonstrate that BL may have the potential to prevent obesity and NAFLD by modulating the mRNA expression of renin-angiotensin system components.
Keywords: gut microbiota; non-alcoholic fatty liver disease; obesity; renin-angiotensin system.
Research Insights
Supplement | Health Outcome | Effect Type | Effect Size |
---|---|---|---|
Bifidobacterium longum BL03 | Improved Glucose Tolerance | Beneficial | Moderate |
Bifidobacterium longum BL03 | Increased ACE2 Protein Expression | Beneficial | Small |
Bifidobacterium longum BL03 | Increased MASR Expression | Beneficial | Small |
Bifidobacterium longum BL03 | Reduced Adipose Tissue Mass | Beneficial | Moderate |
Bifidobacterium longum BL03 | Reduced Blood Glucose Levels | Beneficial | Moderate |
Bifidobacterium longum BL03 | Reduced Hepatic Fat Accumulation | Beneficial | Moderate |
Bifidobacterium longum BL03 | Reduced Total Cholesterol Levels | Beneficial | Moderate |
Bifidobacterium longum MAK34B12L | Improved Glucose Tolerance | Beneficial | Moderate |
Bifidobacterium longum MAK34B12L | Increased ACE2 Protein Expression | Beneficial | Small |
Bifidobacterium longum MAK34B12L | Increased MASR Expression | Beneficial | Small |
Bifidobacterium longum MAK34B12L | Reduced Adipose Tissue | Beneficial | Moderate |
Bifidobacterium longum MAK34B12L | Reduced Blood Glucose Levels | Beneficial | Moderate |
Bifidobacterium longum MAK34B12L | Reduced Hepatic Fat Accumulation | Beneficial | Moderate |
Bifidobacterium longum MAK34B12L | Reduced Total Cholesterol Levels | Beneficial | Moderate |